Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Disease Overview: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and “atypical smoldering multiple myeloma or monoclonal gammopathy undetermined significance (MGUS).”. Diagnosis: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple-green birefringence is required for diagnosis. Invasive organ biopsy is not required in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. The gold standard is laser capture mass spectroscopy. Prognosis: N-terminal pro-brain natriuretic peptide (NT-proBNP), serum troponin T, and difference between involved and uninvolved immunoglobulin free light chain (FLC) values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months. Therapy: All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include systolic blood pressure >90 mmHg, troponin T < 0.06 ng/mL and serum creatinine ≤1.7 mg/dL. Nontransplant candidates can be offered cyclophosphamide-bortezomib-dexamethasone or daratumumab-containing regimens as it appears to be highly active in AL amyloidosis. Future Challenges: Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end-stage organ failure.

Original languageEnglish (US)
Pages (from-to)848-860
Number of pages13
JournalAmerican journal of hematology
Volume95
Issue number7
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment'. Together they form a unique fingerprint.

Cite this